Business
Bruker Supports International Covid19-NMR Consortium for Structure-Function and Inhibitor Binding Investigations of SARS-CoV-2 RNA and Proteins
FRANKFURT, Germany--(BUSINESS WIRE)-- Bruker Corporation (Nasdaq: BRKR) today announced its support of a worldwide collaborative project that investigates
About this update from Bruker Corporation
[{"type":"text","content":" FRANKFURT, Germany--(BUSINESS WIRE)--\nBruker Corporation (Nasdaq: BRKR) today announced its support of a worldwide collaborative project that investigates the structures, dynamics, function and binding of SARS-CoV-2 viral RNA and proteins using high-field nuclear magnetic resonance (NMR) spectroscopy. The Covid19-NMR (https://covid19-nmr.de/) consortium was initiated at Goethe University (GU) in Frankfurt, Germany, and leverages the extensive experience of the GU Biological Magnetic Resonance Center (http://www.bmrz.de/) and of 30 consortium groups in 15 countries in high-field NMR, structural biology, and small molecule drug screening.\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200810005136/en/(Photo: Business Wire)\n\nThe fight against the global COVID-19 pandemic is one of the greatest challenges currently facing mankind. The international Covid19-NMR consortium aims to determine the dynamics, function and potential for therapeutic intervention of the ribonucleic acid (RNA) and protein structures of SARS-CoV-2, with a focus on investigating the potential of small molecule drugs to bind to these viral biopolymer structures. The results are made publicly available prior to publication in order to communicate progress quickly and to a wide research network.\n\n\nGoethe University-Professor Harald Schwalbe, a founder and the coordinator of the Covid19-NMR consortium, commented: “Since the beginning of the Covid19-NMR project, we have collaborated closely with Bruker. Bruker offers us access to its research facilities, support for our NMR spectrometers, as well as analysis software. The Covid19-NMR consortium, now with 140 researchers in 30 research groups in Europe, the Americas and India, benefits greatly from this collaboration, and we are fortunate to have Bruker as a key partner.”\n\n\nThe SARS-CoV-2 virus is comprised of almost 30,000 nucleotides in the RNA genome, which encode for around 30 proteins. The Covid19-NMR consortium has focused on NMR-based determination of secondary structures of the cis-regulatory structured RNA elements in the 5’- and 3’-UTRs of the viral genome, and the consortium has carried out fragment-based ligand screening of RNA target structures using both Bruker and consortium member NMR libraries.\n\n\nAs an example, high-resolution...